1 Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Microbiología, Inmunología y Biotecnología, Cátedra de Inmunología, Junín 956, 1113 Ciudad Autónoma de Buenos Aires, Argentina.
2 CONICET - Universidad de Buenos Aires. Instituto de Estudios de la Inmunidad Humoral 'Prof. Dr. Ricardo A. Margni' (IDEHU), Junín 956, 1113 Ciudad Autónoma de Buenos Aires, Argentina.
Benef Microbes. 2018 Jun 15;9(4):553-562. doi: 10.3920/BM2017.0081. Epub 2018 Apr 10.
Vaccination against pathogens involved in bovine respiratory disease (BRD) is a useful tool to reduce the risk of this disease however, it has been observed that the commercially available vaccines only partially prevent the infections caused by Pasteurella multocida and Mannheimia haemolytica. Therefore, it is recommended to search for new adjuvant strategies to minimise the economic impact of this respiratory syndrome. A possibility to improve the conventional vaccine response is to modulate the immune system with probiotics, since there is accumulating evidence that certain immunomodulatory strains administered around the time of vaccination can potentiate the immune response. Considering veterinary vaccines are frequently tested in murine models, we have developed an immunisation schedule in BALB/c mice that allows us to study the immune response elicited by BRD vaccine. In order to evaluate a potential strategy to enhance vaccine efficacy, the adjuvant effect of Enterococcus faecalis CECT7121 on the murine specific humoral immune response elicited by a commercial vaccine against BRD was studied. Results indicate that the intragastric administration of E. faecalis CECT7121 was able to induce an increase in the specific antibody titres against the bacterial components of the BRD vaccines (P. multocida and M. haemolytica). The quality of the humoral immune response, in terms of antibody avidity, was also improved. Regarding the cellular immune response, although the BRD vaccination induced a low specific secretion of cytokines in the spleen cell culture supernatants, E. faecalis CECT7121-treated mice showed higher interferon-γ production than immunised control mice. Our results allowed us to conclude that the administration of E. faecalis CECT7121 could be employed as an adjuvant strategy to potentiate humoral immune responses.
针对牛呼吸道疾病(BRD)相关病原体的疫苗接种是降低该病风险的有效手段,但据观察,市售疫苗仅能部分预防多杀性巴氏杆菌和溶血曼海姆菌引起的感染。因此,建议寻找新的佐剂策略,以最大限度地降低这种呼吸道综合征的经济影响。改善常规疫苗反应的一种可能性是通过益生菌来调节免疫系统,因为越来越多的证据表明,在接种疫苗时使用某些免疫调节菌株可以增强免疫反应。鉴于兽医疫苗经常在鼠模型中进行测试,我们在 BALB/c 小鼠中制定了免疫方案,使我们能够研究 BRD 疫苗引起的免疫反应。为了评估增强疫苗效力的潜在策略,研究了粪肠球菌 CECT7121 对商业 BRD 疫苗引起的小鼠特异性体液免疫反应的佐剂效应。结果表明,粪肠球菌 CECT7121 的胃内给药能够诱导针对 BRD 疫苗中细菌成分(多杀性巴氏杆菌和溶血曼海姆菌)的特异性抗体滴度增加。抗体亲和力方面,体液免疫反应的质量也得到了改善。关于细胞免疫反应,尽管 BRD 疫苗接种诱导了脾细胞培养上清液中细胞因子的低特异性分泌,但粪肠球菌 CECT7121 处理的小鼠比免疫对照小鼠表现出更高的干扰素-γ产生。我们的结果表明,粪肠球菌 CECT7121 的给药可以作为增强体液免疫反应的佐剂策略。